Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- (-) Low-Value Care
- Pandemic Response
- (-) Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- (-) Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 54 Results
Skyrocketing Deductibles Should Be a Focus of Open-Enrollment Season
The dizzyingly complex process of shopping for health insurance can obscure some of the most important factors in making a choice.
Pharmacists Can Help the Pharmaceutical Ecosystem Work Better for Patients
In a commentary, NPC President and CEO John O’Brien reflects on his personal experience as a pharmacist and how that training led him on the path to a career in health policy.
Join NPC at ISPOR 2022
Join NPC at ISPOR 2022 for presentations and a student session and visit us at our exhibit booth.
Health Spending Post-Pandemic: Looking for High Value Beyond the Headlines
NPC Chief Science Officer Dr. Sharon Phares takes a closer look at CMS' national health expenditure report and what their predictions mean for our health care system.
Drug Price Regulation Trade-offs: Real or Imagined?
NPC hosted a panel at AcademyHealth’s National Health Policy Conference to explore the potential risks and unintended consequences of drug price regulation.
High Patient Out-of-Pocket Costs Lead to Worse Medication Adherence Without Overall Health Care Savings
Research from NPC and Xcenda suggests that high cost-sharing for prescription medications may have negative effects on patient health while not actually decreasing overall health care costs. …
Women Leaders Are Making a Difference
In celebration of Women's History Month, NPC asked our women Board members to share their insights on the importance of having women in leadership and their advice to young leaders.
Why Patients Are Paying More at the Pharmacy Counter in Early 2022 - And What We Can Do to Fix It
NPC Immediate Past Board Chair Mike Ryan and CSO Sharon Phares explore policy solutions to ensure patients can have predictable and affordable out-of-pocket costs for medicines.
NPC Chair Shares His Outlook for an Energized Organization
In his first post as Board chair, Mallinckrodt Pharmaceuticals' Dr. Steven Romano says NPC is in a strong position to lead health policy debates through new leadership, dedicated staff experts and an…
Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries
Proposals seeking to improve access for Medicare beneficiaries should ensure that patients are better able to get the medicines their doctors say they need.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
Kimberly Westrich Talks Benefit Design with AJMC
NPC's Vice President of Health Services Research, Kimberly Westrich, MA, discusses how the healthcare system can incentivize high-value care.
NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients
In a commentary for RealClearPolicy, NPC’s John M. O’Brien explains how the drug pricing deal in the Build Back Better Act could create harmful unintended consequences for patient health and the…
Drug Spending Mirrors Spending on Other Health Care Services
Spending on prescription drugs is not an anomaly but rather follows similar patterns as other health care services. Policy proposals that focus narrowly on constraining drug spending are…
A Healthier Country Means Lower Health Care Spending
The U.S. spends twice as much per person on health care compared to other wealthy countries. While higher U.S. health care prices play a role in this disparity, they are not the only cause. A new NPC…
Building a Better Evidence Base to Address the Social Determinants of Health
The COVID-19 pandemic has put a spotlight on the pressing need to address social determinants of health (SDOH). NPC's Dr. Dubois examines the gaps within the existing evidence base and how…
What the Data Are Saying on Drug Pricing and Utilization
NPC President and CEO John O'Brien discusses the IQVIA Institute’s new report and takes a closer look at the factors that are driving medication use and health care spending in the United States.
NPC’s New Leader: Merging Research and Data with Real-World Experience
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
Walking the Walk: Taking Needed Steps to Reduce Low-Value Care
Three leading researchers detail steps to reduce low-value care in the latest edition of The American Journal of Managed Care. Their approach complements a similar effort, the Roadmap for…
Let’s Work Together to Improve Our Health Care System
NPC's new president and CEO outlines his commitment to working with all partners, across all sectors, to improve our health care system.